To green-catalyze the synthesis of aspirin, we designed and synthesized a novel and unreported cadmium phosphomolybdate crystal compound (C2N2H10)4{Cd3[P4Mo6O26(OH)5]2}·6H2O as a catalyst for the synthesis reaction of aspirin using hydrothermal synthesis, and structurally characterized. Single-crystal X-ray diffraction analysis showed that the compound has a 4,8-connected inorganic open topology (412·612·84)(46)2. The optimal process conditions for the reaction of salicylic acid and acetic anhydride were determined by screening the catalyst dosage, temperature, and reaction time. The reaction temperature was set at 80 °C, the catalyst dosage was 0.09 g, and the reaction time was 25 min. The industry's most often utilized catalyst for aspirin manufacturing is concentrated sulfuric acid, which has strong oxidizing and corrosive qualities, resulting in difficult issues such as low synthetic product yield, large equipment needs, and substantial environmental damage. The experimental results of the (C2N2H10)4{Cd3[P4Mo6O26(OH)5]2}·6H2O catalytic synthesis of aspirin reveal that as a solid acid catalyst, its catalytic activity is similar to the commonly used catalyst concentrated H2SO4. Synthetic catalysts, on the other hand, have the advantages of high efficiency, selectivity, conversion rate, ease of recovery, and the ability to be recycled several times without polluting equipment, all of which are consistent with modern ``green'' catalysts. The results of this work suggest that the supramolecular compounds of polymetallic oxonate that we designed and produced hydrothermally can serve as catalysts in drug synthesis reactions to mitigate environmental pollution, hence providing new opportunities for the development of environmentally friendly medications.
Read full abstract